Abstract: A method of ink-extrusion printing an object, including providing a mixture including liquid crystal monomers and photo-catalyzing or heating the mixture to produce a liquid crystal ink. The ink is in a nematic phase. The method includes extruding the ink through a print-head orifice moving along a print direction to faun an extruded film of the object. The extruded film exhibits birefringence. Also disclosed are a liquid crystal ink. The ink includes a mixture including liquid crystal monomers. The mixture when at a target printing temperature is in a nematic phase. Also disclosed is ink-extrusion-printed object. The object includes an extrusion-printed film including a nematic liquid crystal elastomer, wherein the film exhibits birefringence along an extrusion axis of the film.

Abstract: Methods for detecting colorectal cancer or precancerous conditions such as adenomatous polyps in a subject by detection of a galactose-containing 40-kDa molecule in a serum sample from the subject are provided. Methods for quantifying the amount of a galactose-containing molecule in a serum sample are also provided. The methods can further comprise assaying the sample for the quantity of at least one additional marker to confirm the detection or diagnosis of colorectal cancer using one or more additional quantitative immune-detection assays; the additional marker can be at least one of galectin-3, a peptide derived from galectin-3, carcinoembryonic antigen (CEA), and CYFRA21-1.

Abstract: This disclosure includes an imaging system that is configured to image in parallel multiple focal planes in a sample uniquely onto its corresponding detector while simultaneously reducing blur on adjacent image planes. For example, the focal planes can be staggered such that fluorescence detected by a detector for one of the focal planes is not detected, or is detected with significantly reduced intensity, by a detector for another focal plane. This enables the imaging system to increase the volumetric image acquisition rate without requiring a stronger fluorescence signal. Additionally or alternatively, the imaging system may be operated at a slower volumetric image acquisition rate (e.g., that of a conventional microscope) while providing longer exposure times with lower excitation power. This may reduce or delay photo-bleaching (e.g., a photochemical alteration of the dye that causes it to no longer be able to fluoresce), thereby extending the useful life of the sample.

Abstract: Embodiments provided here include recombinant polypeptides, termed degradons, comprising a target binding domain and a proteasome-binding domain. Degradons of the embodiments are able to selectively target and degrade proteins bound by the target-binding domain, such as proteins associated with disease. Vectors encoding degradons and methods of treating disease with degradons and degradon expression vectors are likewise provided.

Abstract: The present invention provides methods of detecting cancer using biomarkers.

Abstract: Disclosed herein are compositions and methods for reducing fluid loss in a well bore. Also disclosed herein are methods for wellbore strengthening and increasing the integrity of the borehole of an oil or gas well. In particular, disclosed are methods for artificially increasing the temperature of a subsurface formation in the wellbore to increase the apparent wellbore strength.

Abstract: Antibodies that selectively bind to glycosylated PD-1 relative to unglycosylated PD-1 are provided. In some aspects, PD-1 polypeptides comprising glycosylated amino acid positions are also provided. Methods for making and using such antibodies and polypeptides (e.g., for the treatment of cancer) are also provided.

Abstract: The present invention provides methods of diagnosing and prognosing disease by analyzing the methylation status of exosomal DNA. In particular, exosomal DNA, in particular exosomal DNA isolated from exosomes that originated from a diseased cell, is analyzed for either a global methylation fingerprint or for a particular methylation status at one or more genomic loci, thereby providing information regarding the disease-state of the originated cell.

Abstract: The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to SLC6A1 loss and/or misfunction. The methods and compositions of the present disclosure comprise rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules comprising nucleic acid sequences encoding for a GAT1 polypeptide.

Abstract: Disclosed embodiments include systems and methods for archiving complete radiation records for transmission and review. In various embodiments, the radiation therapy archiving system miniaturizes some of the essential features of radiation therapy planning systems including radiation therapy data reading and writing capabilities, functionality for representing contoured objects and other radiation therapy specific features, and functionality for viewing radiation therapy plans. Compact radiation therapy datasets generated by the radiation therapy archiving system may accurately represent previous radiation doses administered to a patient. To help patients transition from one radiation therapy clinic to a remote clinic, radiation therapy datasets may be downloaded to a personal computer and transferred a remote treatment planning system to be used during the design phase of ongoing radiation therapy treatments.

Abstract: The present disclosure provides methods and compositions for the treatment of diseases and genetic disorders linked to SURF1 loss and/or misfunction. The methods and compositions of the present disclosure comprise rAAV vectors and rAAV viral vectors comprising transgene nucleic acid molecules comprising nucleic acid sequences encoding for a SURF1 polypeptide.

Abstract: Described are compounds and methods useful in the treatment of Fuchs' Endothelial Corneal Dystrophy (FECD).

Abstract: The present disclosure is directed to bispecific antibodies which bind to both PD-L1 and PD-L2, and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1, PD-L2, or both.

Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.

Abstract: Nanoscale, pH-responsive polycationic networks useful for the delivery of anionic biologic therapeutics and associated methods.

Abstract: Provided are T cell receptors (TCR) and TCR variable regions that can selectively bind the T-cell leukemia/lymphoma 1 (TCL1) oncoprotein. The TCR may be utilized in various therapies, such as autologous TCL1-TCR adoptive T cell therapy, to treat a cancer, such as a B-cell malignancy or a solid tumor expressing TCL1. Methods for expanding a population of T cells that target TCL1 are also provided.

Abstract: The present disclosure provides methods for molecular neighborhood detection of molecules, such as by iterative proximity ligation or split-and-pool methods for obtaining positional information.

Abstract: Methods for increasing immune therapy response and predicting likelihood of cancer metastasis by analyzing the expression of genes associated with replication stress response. In some aspects, cancers are treated with immune checkpoint inhibitors and/or MEK inhibitors. Methods for selecting patients by analyzing the expression of genes associated with a defect in replication stress response are also provided.

Abstract: The present disclosure relates to pharmaceutical formulations including a weakly basic drug and an ionic polymer in an amorphous solid dispersion, as well as methods of forming such pharmaceutical formulations, and methods of administering such pharmaceutical formulations.

Abstract: In some aspects, the present disclosure provides methods of aminating an aromatic compound comprising reacting an aminating agent with an aromatic compound in the presence of a rhodium catalyst. In some embodiments, the methods may comprise aminating an aromatic compound which contains multiple different functional groups. The methods described herein may also be used to create bicyclic system comprising reacting an intramolecular aminating agent with an aromatic ring to obtain a second ring containing a nitrogen atom. In another aspect, the methods described herein may also be used to create a cyclic aliphatic cyclic/poly cyclic amine system comprising a reacting an intramolecular aminating agent by insertion into a C(sp3)-H bond.